CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.1200
+0.2000 (+1.55%)
As of 9:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.9200
Open13.0000
Bid12.9400 x 900
Ask13.1500 x 800
Day's Range13.0000 - 13.1700
52 Week Range7.4200 - 17.6350
Volume4,420
Avg. Volume88,479
Market Cap383.02M
Beta-2.28
PE Ratio (TTM)N/A
EPS (TTM)-2.5620
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.60
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

    BURLINGAME, Calif., May 30, 2018-- Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today ...

  • Associated Press2 months ago

    Corvus: 1Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 63 cents. Corvus shares have decreased 9 percent since the beginning of the year. In the final minutes of trading on ...

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first quarter ended March 31, 2018, and provided a business update. “We made important progress in advancing our clinical programs and building our pipeline, with several notable developments in the first quarter that reinforce our continued leadership in the development of therapies targeting the adenosine pathway,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We are now enrolling patients in our Phase 1/1b trial evaluating CPI-006 as a monotherapy, in combination with CPI-444 and in combination with Keytruda® (pembrolizumab).  We believe this is the first human clinical trial in oncology to evaluate the effect of dual-blockade of the adenosine pathway by inhibiting both CD73 and the A2A receptor.  With the initiation of this new trial and our ongoing Phase 1/1b clinical trial with our A2A receptor antagonist CPI-444, we continue to have one of the most advanced programs addressing the adenosine pathway.

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73. The three-arm study in patients with a variety of solid tumors is evaluating CPI-006 administered as a single agent, in combination with Corvus’ CPI-444, a selective and potent inhibitor of the adenosine A2A receptor, and in combination with pembrolizumab, an anti-PD-1 antibody. “CPI-006 is an antibody engineered to completely inhibit the CD73 enzyme by binding to its active site. We look forward to evaluating this anti-CD73 antibody in our comprehensive Phase 1/1b trial, which we believe is the first human clinical trial in oncology to evaluate the effect of dual-blockade of the adenosine pathway by inhibiting both CD73 and the A2A receptor,” said Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus.

  • ACCESSWIRE3 months ago

    Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting

    Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...

  • Associated Press4 months ago

    Corvus reports 4Q loss

    On a per-share basis, the Burlingame, California-based company said it had a loss of 58 cents. For the year, the company reported that its loss widened to $55.7 million, or $2.72 per share. Corvus shares ...

  • Associated Press10 months ago

    Corvus reports 2Q loss

    The Burlingame, California-based company said it had a loss of 73 cents per share. Corvus shares have fallen 16 percent since the beginning of the year. The stock has fallen 7.5 percent in the last 12 ...